Dr. Jon Salmanton-García discusses unmet needs in preventing and treating respiratory infections in haematology patients, highlighting real-world data insights and the urgent need for targeted vaccines and antivirals.

Respiratory syncytial virus (RSV) is often of increased concern in the autumn and winter months, especially for women who are pregnant, or those with newborns.1 Worldwide, RSV is the second leading cause of death (second to malaria) in children during ...

HIV vaccine development, emphasizing HIV, RSV, and coronavirus COVID-19 research is discussed by Prof. Barney Graham. This information is crucial for immunologists, virologists, and those in vaccine research. Learn from cross-disciplinary strategies. You, as healthcare professionals in these fields, need to grasp these insights for innovation. HIV, RSV, and coronavirus studies offer valuable lessons. Keep up with the latest in vaccine technology.

Initial attempts to develop a HIV vaccine focused on creating a vaccine that would generate neutralizing antibodies against the virus, using portions of the HIV envelope from prototype laboratory isolates. The initial attempts using monomeric envelope proteins of largely laboratory ...

Respiratory syncytial virus (RSV) present a significant disease burden in children and older adults. Currently, there are no approved vaccines against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, ...

Respiratory syncytial virus (RSV) presents a significant disease burden in older adults, with no approved vaccines to protect against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) ...

In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss his highlights from IDWeek 2022. He highlights vaccine development applied outside of COVID-19, and transformational RSV vaccines, antivirals, antifungals ...

Following the recent results from the pivotal Phase III MELODY and Phase IIb trials of nirsevimab in the treatment of respiratory syncytial virus, we were delighted to speak with Dr. Joseph Domachowske (Upstate University Hospital, Syracuse, NY, USA) to discuss ...

Following the recent phase III and phase IIb data for nirsevimab in the treatment of respiratory syncytial virus (RSV), we were delighted to speak with Dr. Joseph Domachowske (Upstate University Hospital, Syracuse, NY, USA) to discuss the unmet needs in ...